Alvotech

Better Access. Better Lives.

We are led by science, driven by passion, and committed to biosimilars. We are continually evaluating additional pipeline opportunities to bring a strategic and robust selection of treatment options to patients around the world.

AVT02

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
High-concentration, low-volume adalimumab
Reference biologic
HUMIRA®
Therapeutic area
Immunology

Approved by

  • U.S.
  • Europe (EEA, UK, Switzerland, Balkans)
  • Canada
  • Australia
  • Saudi Arabia
  • Israel
  • Egypt
  • South Africa
  • Morocco
  • Peru
  • Bolivia

AVT04

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
ustekinumab
Reference biologic
STELARA®
Therapeutic area
Immunology

Approved by

  • U.S.
  • Japan
  • Canada
  • EU/EEA

AVT03

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
denosumab
Reference biologic
PROLIA®/XGEVA®
Therapeutic area
Bone Disease

Approved by

  • Japan
  • EU/EEA
  • United Kingdom

AVT05

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
golimumab
Reference biologic
SIMPONI®/SIMPONI ARIA®
Therapeutic area
Immunology

Approved by

  • Japan
  • EU/EEA
  • United Kingdom

AVT06

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
aflibercept
Reference biologic
EYLEA®
Therapeutic area
Ophthalmology

Approved by

  • Japan
  • EU/EEA
  • United Kingdom

AVT23*

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
omalizumab
Reference biologic
XOLAIR®
Therapeutic area
Respiratory

Approved by

  • United Kingdom

AVT16

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
vedolizumab
Reference biologic
ENTYVIO® (intraveneous injection)
Therapeutic area
Immunology

AVT80

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
vedolizumab
Reference biologic
ENTYVIO® (subcutaneous injection)
Therapeutic area
Immunology

AVT29

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
aflibercept
Reference biologic
EYLEA® HD
Therapeutic area
Ophthalmology

AVT32

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
pembrolizumab
Reference biologic
KEYTRUDA®
Therapeutic area
Oncology

AVT10

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
certolizumab pegol
Reference biologic
CIMZIA®
Therapeutic area
Immunology

AVT28

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
ixekizumab
Reference biologic
TALTZ®
Therapeutic area
Immunology

AVT48

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
canakinumab
Reference biologic
ILARIS®
Therapeutic area
Immunology

AVT41

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
guselkumab
Reference biologic
TREMFYA®
Therapeutic area
Immunology

AVT65

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
ofatumumab
Reference biologic
KESIMPTA®
Therapeutic area
Immunology

AVT19

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
dupilumab
Reference biologic
DUPIXENT®
Therapeutic area
Immunology

AVT87

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
emicizumab
Reference biologic
HEMLIBRA®
Therapeutic area
Hematology

AVT34

  • Early Phase
  • Pre-clinical
  • Clinical Trials
  • Filing
  • Approval
  • Launch
Biosimilar candidate
durvalumab
Reference biologic
IMFINZI®
Therapeutic area
Oncology

HUMIRA is a registered trademark of AbbVie Inc.
STELARA, SIMPONI , SIMPONI ARIA and TREMFYA are registered trademarks of Johnson & Johnson Inc. 
XOLAIR, ILARIS and KESIMPTA is a registered trademark of Novartis AG.
PROLIA and XGEVA are registered trademarks of Amgen Inc.
EYLEA is a registered trademarks of Regeneron Pharmaceuticals Inc. and Bayer AG. 
ENTYVIO is a registered trademark of Millenium Pharmaceuticals Inc. 
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp.
CIMZIA is a registered trademark of UCB Pharma S.A.
DUPIXENT is a registered trademark of Sanofi Biotechnology.
TALTZ is a registered trademark of Eli Lilly and Company.

HEMLIBRA is a registered trademark of Chugai Pharmaceutical Co.

IMFINZI is a registered trademark of the AstraZeneca group of companies